keyword
MENU ▼
Read by QxMD icon Read
search

Lanreotide

keyword
https://www.readbyqxmd.com/read/29923433/somatostatin-analogue-induced-pancreatic-exocrine-insufficiency-in-patients-with-neuroendocrine-tumours-results-of-a-prospective-observational-study
#1
Angela Lamarca, Lynne McCallum, Christina Nuttall, Jorge Barriuso, Alison Backen, Melissa Frizziero, Rebecca Leon, Was Mansoor, Mairéad G McNamara, Richard A Hubner, Juan W Valle
Background Patients with advanced well-differentiated neuroendocrine tumours(Wd-NETs) are commonly treated with somatostatin analogues(SSAs). Some patients may develop SSA-related side effects such as pancreatic exocrine insufficiency(PEI). Methods In this single-institution, prospective, observational study, the frequency of SSA-induced PEI in 50 sequential patients with advanced Wd-NETs treated with SSAs was investigated. Toxicity was assessed monthly and faecal elastase-1 (FE1) and quality of life (QoL) were assessed 3-monthly...
June 20, 2018: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29888099/lanreotide-in-the-prevention-and-management-of-high-output-ileostomy-after-colorectal-cancer-surgery
#2
Pieter-Jan Cuyle, Anke Engelen, Veerle Moons, Tim Tollens, Saskia Carton
Objective: Patients with stage III and high-risk stage II colorectal cancer (CRC) are advised to initiate adjuvant treatment as soon as feasible and certainly before 8 to 12 weeks after resection of the tumor. A protective ileostomy is often constructed during surgery to protect a primary anastomosis "at risk", especially in rectal cancer surgery. However, up to 17% of patients with a stoma suffer from high output, a major complication that can prevent adjuvant treatment implementation or completion...
2018: Journal of Drug Assessment
https://www.readbyqxmd.com/read/29767287/screening-for-comorbid-conditions-in-patients-enrolled-in-the-soda-registry-a-2-year-observational-analysis
#3
Whitney W Woodmansee, Murray B Gordon, Mark E Molitch, Adriana G Ioachimescu, Don W Carver, Beloo Mirakhur, David Cox, Roberto Salvatori
PURPOSE: This 2-year analysis assessed frequency of comorbidities and comorbidity screening in the Somatuline® (lanreotide, LAN) Depot for Acromegaly (SODA) registry. METHODS: Patient data collected included pituitary hormone deficiencies, sleep studies, echocardiograms, gallbladder sonographies, colonoscopies, and glycated hemoglobin (HbA1c) levels. Insulin-like growth factor-1 (IGF-1) and growth hormone levels in patients with (DM) and without (non-DM) diabetes mellitus were analyzed...
May 16, 2018: Endocrine
https://www.readbyqxmd.com/read/29720885/successful-second-line-metronomic-temozolomide-in-metastatic-paraganglioma-case-reports-and-review-of-the-literature
#4
Isabel Tena, Garima Gupta, Marcos Tajahuerce, Marta Benavent, Manuel Cifrián, Alejandro Falcon, María Fonfria, Maribel Del Olmo, Rosa Reboll, Antonio Conde, Francisca Moreno, Julia Balaguer, Adela Cañete, Rosana Palasí, Pilar Bello, Alfredo Marco, José Luis Ponce, Juan Francisco Merino, Antonio Llombart, Alfredo Sanchez, Karel Pacak
Metastatic pheochromocytoma and paraganglioma (mPHEO/PGL) are frequently associated with succinate dehydrogenase B ( SDHB ) mutations. Cyclophosphamide-dacarbazine-vincristine (CVD) regimen is recommended as standard chemotherapy for advanced mPHEO/PGL. There is limited evidence to support the role of metronomic schemes (MS) of chemotherapy in mPHEO/PGL treatment. We report 2 patients with SDHB -related mPGL who received a regimen consisting of MS temozolomide (TMZ) and high-dose lanreotide after progression on both CVD chemotherapy and high-dose lanreotide...
2018: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/29655834/metformin-use-associates-with-longer-progression-free-survival-of-patients-with-diabetes-and-pancreatic-neuroendocrine-tumors-receiving-everolimus-and-or-somatostatin-analogues
#5
Sara Pusceddu, Claudio Vernieri, Massimo Di Maio, Riccardo Marconcini, Francesca Spada, Sara Massironi, Toni Ibrahim, Maria Pia Brizzi, Davide Campana, Antongiulio Faggiano, Dario Giuffrida, Maria Rinzivillo, Sara Cingarlini, Francesca Aroldi, Lorenzo Antonuzzo, Rossana Berardi, Laura Catena, Chiara De Divitiis, Paola Ermacora, Vittorio Perfetti, Annalisa Fontana, Paola Razzore, Carlo Carnaghi, Maria Vittoria Davì, Carolina Cauchi, Marilina Duro, Sergio Ricci, Nicola Fazio, Federica Cavalcoli, Alberto Bongiovanni, Anna La Salvia, Nicole Brighi, Annamaria Colao, Ivana Puliafito, Francesco Panzuto, Silvia Ortolani, Alberto Zaniboni, Francesco Di Costanzo, Mariangela Torniai, Emilio Bajetta, Salvatore Tafuto, Silvio Ken Garattini, Daniela Femia, Natalie Prinzi, Laura Concas, Giuseppe Lo Russo, Massimo Milione, Luca Giacomelli, Roberto Buzzoni, Gianfranco Delle Fave, Vincenzo Mazzaferro, Filippo de Braud
BACKGROUND & AIMS: Metformin seems to have anti-cancer effects. However, it is not clear whether use of glycemia and metformin affect outcomes of patients with advanced pancreatic neuroendocrine tumors (pNETs). We investigated the association between glycemia and progression-free survival (PFS) of patients with NETs treated with everolimus and/or somatostatin analogues, as well as the association between metformin use and PFS time. METHODS: We performed a retrospective analysis of 445 patients with advanced pNET treated at 24 medical centers in Italy, from 1999 through 2015...
April 12, 2018: Gastroenterology
https://www.readbyqxmd.com/read/29643113/pasireotide-in-the-treatment-of-neuroendocrine-tumors-a-review-of-the-literature
#6
REVIEW
Giovanni Vitale, Alessandra Dicitore, Concetta Sciammarella, Sergio Di Molfetta, Manila Rubino, Antongiulio Faggiano, Annamaria Colao
Somatostatin analogs have an important role in the medical therapy of neuroendocrine tumors (NETs). Octreotide and lanreotide, both somatostatin analogs binding with high affinity for the somatostatin receptor (SSTR)2, can control symptoms in functional NETs. In addition, these compounds, because of their antiproliferative effects, can stabilize growth of well-differentiated NETs. Pasireotide is a novel multireceptor-targeted somatostatin analog with high affinity for SSTR1, 2, 3, and 5. This review provides an overview of the state of the art of pasireotide in the treatment of NETs, with the aim of addressing clinical relevance and future perspectives for this molecule in the management of NETs...
June 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29590371/somatostatin-analogs-and-glucose-metabolism-in-acromegaly-a-meta-analysis-of-prospective-interventional-studies
#7
Alessia Cozzolino, Tiziana Feola, Ilaria Simonelli, Giulia Puliani, Carlotta Pozza, Elisa Giannetta, Daniele Gianfrilli, Patrizio Pasqualetti, Andrea Lenzi, Andrea M Isidori
Introduction: Somatostatin analogs (SSAs) effectivelycontrol growth hormone secretion in first and second line treatmentof acromegaly. Their effect onglucose metabolism is still debated. Aim: to address the following questions: 1) Do SSAs affect fasting plasma glucose (FPG), fasting plasma insulin (FPI), glycosylated hemoglobin (HbA1c), glucose load (2h-OGTT), HOMA-I, HOMA-β, triglycerides (TGD), weight (W) or body mass index (BMI)? 2) Do lanreotide (LAN) and octreotide LAR (OCT) affect metabolism differently? 3)Does their effect depend on disease control? Methods: We performed a meta-analysis of prospective interventional trialstreating acromegaly with SSAs...
March 23, 2018: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29563895/novel-somatostatin-receptor-ligands-therapies-for-acromegaly
#8
REVIEW
Rosa Maria Paragliola, Roberto Salvatori
Surgery is considered the treatment of choice in acromegaly, but patients with persistent disease after surgery or in whom surgery cannot be considered require medical therapy. Somatostatin receptor ligands (SRLs) octreotide (OCT), lanreotide, and the more recently approved pasireotide, characterized by a broader receptor ligand binding profile, are considered the mainstay in the medical management of acromegaly. However, in the attempt to offer a more efficacious and better tolerated medical approach, recent research has been aimed to override some limitations related to the use of currently approved drugs and novel SRLs therapies, with potential attractive features, have been proposed...
2018: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29558899/efficacy-and-safety-of-everolimus-treatment-in-a-hemodialysis-patient-with-metastatic-atypical-bronchial-carcinoid-case-report-and-literature-review
#9
M P Brizzi, A La Salvia, M Tampellini, C Sonetto, M Volante, G V Scagliotti
BACKGROUND: Everolimus was recently approved for the treatment of neuroendocrine tumors. However, its efficacy and tolerability in hemodialysis patients with end-stage renal disease is not established. CASE PRESENTATION: We describe the case of a 47-year-old man with end-stage renal disease who received everolimus plus Lanreotide for 9 months for the management of metastatic atypical bronchial carcinoid. CONCLUSIONS: Everolimus is a treatment option for hemodialysis patients with metastatic atypical bronchial carcinoid...
March 20, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29547049/lanreotide-therapy-in-carcinoid-syndrome-prospective-analysis-of-patient-reported-symptoms-in-patients-responsive-to-prior-octreotide-therapy-and-patients-na%C3%A3-ve-to-somatostatin-analogue-therapy-in-the-elect-phase-3-study
#10
RANDOMIZED CONTROLLED TRIAL
George A Fisher, Edward M Wolin, Nilani Liyanage, Susan Pitman Lowenthal, Beloo Mirakhur, Rodney F Pommier, Montaser Shaheen, Aaron I Vinik
OBJECTIVE: This ELECT prospective analysis examined lanreotide depot/autogel for carcinoid syndrome (CS) symptom control in patients with neuroendocrine tumors (NETs) who were responsive to prior octreotide (prior octreotide group) compared with patients who were naïve to prior somatostatin analogue treatment (de novo group). METHODS: Adults with histopathologically confirmed NET and stable CS (diarrhea and/or flushing) were randomized to subcutaneous (SC) lanreotide 120 mg or placebo every 4 weeks for 16 weeks...
March 2018: Endocrine Practice
https://www.readbyqxmd.com/read/29466059/initiation-of-patients-onto-long-acting-somatostatin-analogue-therapy-for-neuroendocrine-tumors-a-single-center-review-of-practice
#11
Michael Tadman, Philip Charlton, Bahram Jafar-Mohammadi, Denis Talbot, Ashley B Grossman
OBJECTIVE: Neuroendocrine tumors (NETs) are being seen increasingly frequently, and recent data show that long-acting somatostatin analogues have become a major initial treatment, regardless of whether the tumors are functioning or not. However, test dosing with subcutaneous (sc) octreotide is usually advised to assess longer-term tolerability, although this advice is mainly based on results with functioning tumors. The aim of the study was to assess the value of an initiating test dose of sc octreotide on the prediction of subsequent adverse events after treatment with the long-acting analogue...
February 2018: Endocrine Practice
https://www.readbyqxmd.com/read/29430237/downgrading-of-a-g3-neuroendocrine-tumor-to-a-g2-tumor-can-first-line-cytotoxic-chemotherapy-change-the-tumor-biology
#12
Andreas Blesl, Elisabeth Krones, Marion J Pollheimer, Johannes Haybaeck, Ulrike Wiesspeiner, Rainer W Lipp, Patrizia Kump
The antiproliferative treatment options for neuroendocrine tumors (NET)/neuroendocrine carcinomas of the gastrointestinal tract critically depend on the proliferation rate, evaluated by immunohistochemical staining for Ki-67. According to their grading, tumors are treated with somatostatin analogs, mTOR inhibitors, or cytotoxic substances. This case illustrates downgrading of a primarily highly proliferative NET achieved by a variation of cytotoxic chemotherapy regimens, followed by a combination therapy using everolimus together with lanreotide...
September 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/29430219/disease-control-on-lanreotide-autogel%C3%A2-120-mg-in-a-patient-with-metastatic-gastrinoma-a-case-report
#13
Maridi Aerts, Hendrik Reynaert
Gastrinomas are functionally active pancreatic neuroendocrine tumors (NETs) secreting gastrin and are associated with local or regional metastases in 60% of the cases. Somatostatin analogs (SSAs) are currently recommended as a first-line treatment for the symptomatic treatment of NETs. Although antiproliferative activity of SSAs has been demonstrated in various cancer types in several in vivo and in vitro studies, clinical benefits with SSAs have been only achieved in a small proportion of patients. We report a disease control on a long-acting SSA lanreotide in a patient with metastatic gastrinoma...
September 2017: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/29383428/from-initial-description-by-wermer-to-present-day-men1-what-have-we-learned
#14
Nancy D Perrier
INTRODUCTION: Pancreas, parathyroid, and pituitary, are referred to as the "3 Ps" of MEN1. The time has come to move beyond those Ps and begin to discuss (1) prediction, (2) pausing progression, and (3) prevention of MEN1. METHODS: In preparation for the International Association of Endocrine Surgeons State of the Art address, updates and uncertainties of MEN were reviewed. This included a detailed examination of the MEN1 gene and the library of implicated mutations, exon sequencing databases and cell cycle pathways...
April 2018: World Journal of Surgery
https://www.readbyqxmd.com/read/29377286/diagnostic-approach-to-subcutaneous-nodules-in-patients-with-neuroendocrine-tumours-treated-with-depot-somatostatin-analogs-a-cross-sectional-study
#15
P Chicharro, A Paniagua, P Rodríguez-Jiménez, S Ibañes, B Cortina, J Riveiro, M Á Sampedro-Núñez, J Fraga, M Marazuela, E Daudén
BACKGROUND: The presence of cutaneous nodules in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) receiving depot somatostatin analogs (SSAs) is a diagnostic challenge as differential diagnosis between injection site reactions and metastases is essential. OBJECTIVE: To characterize the clinical, radiological, cytological and histopathological features of subcutaneous nodules in patients with GEP-NETs treated with SSAs. MATERIALS AND METHODS: Retrospective, cross-sectional study of patients with GEP-NETs treated with SSAs in whom subcutaneous nodules were detected on routine abdominal computed tomography (CT) scans...
January 29, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29357081/biochemical-efficacy-of-long-acting-lanreotide-depot-autogel-in-patients-with-acromegaly-na%C3%A3-ve-to-somatostatin-receptor-ligands-analysis-of-three-multicenter-clinical-trials
#16
Hussain Alquraini, Maria Del Pilar Schneider, Beloo Mirakhur, Ariel Barkan
PURPOSE: In clinical research involving acromegalic patients naïve to somatostatin-receptor ligands (SRLs), 19 and 31% of those receiving the SRLs octreotide LAR and pasireotide LAR, respectively, achieved GH < 2.5 ng/mL + normalized IGF-1 concentrations. The proportions achieving control appeared higher in the post-surgery compared with the de-novo setting with pasireotide, but more similar with octreotide. Using pooled data from multicenter clinical trials, we examined the biochemical efficacy of lanreotide depot/Autogel in similar settings...
January 22, 2018: Pituitary
https://www.readbyqxmd.com/read/29201453/the-role-of-multimodal-treatment-in-patients-with-advanced-lung-neuroendocrine-tumors
#17
REVIEW
Nicola Fazio, Antonio Ungaro, Francesca Spada, Chiara Alessandra Cella, Eleonora Pisa, Massimo Barberis, Chiara Grana, Dario Zerini, Emilio Bertani, Dario Ribero, Luigi Funicelli, Guido Bonomo, Davide Ravizza, Juliana Guarize, Filippo De Marinis, Francesco Petrella, Ester Del Signore, Giuseppe Pelosi, Lorenzo Spaggiari
Lung neuroendocrine tumors (NETs) comprise typical (TC) and atypical carcinoids (AC). They represent the well differentiated (WD) or low/intermediate grade forms of lung neuroendocrine neoplasms (NENs). Unlike the lung poorly differentiated NENs, that are usually treated with chemotherapy, lung NETs can be managed with several different therapies, making a multidisciplinary interaction a key point. We critically discussed the multimodal clinical management of patients with advanced lung NETs. Provided that no therapeutic algorithm has been validate so far, each clinical case should be discussed within a NEN-dedicated multidisciplinary team...
November 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29038234/patient-reported-symptom-control-of-diarrhea-and-flushing-in-patients-with-neuroendocrine-tumors-treated-with-lanreotide-depot-autogel-results-from-a-randomized-placebo-controlled-double-blind-and-32-week-open-label-study
#18
George A Fisher, Edward M Wolin, Nilani Liyanage, Susan Pitman Lowenthal, Beloo Mirakhur, Rodney F Pommier, Montaser Shaheen, Aaron Vinik
BACKGROUND: In the double-blind (DB) ELECT study, lanreotide depot/autogel significantly reduced versus placebo the need for short-acting octreotide for symptomatic carcinoid syndrome (CS) control in neuroendocrine tumor (NET) patients. Here we present patient-reported symptom data during DB and initial open-label (IOL) treatment. MATERIALS AND METHODS: Adults with NETs and CS history, with/without prior somatostatin analog use, were randomized to 16 weeks' DB lanreotide 120 mg subcutaneous or placebo every 4 weeks, followed by 32 weeks' IOL lanreotide...
January 2018: Oncologist
https://www.readbyqxmd.com/read/28970728/real-world-treatment-patterns-of-gastrointestinal-neuroendocrine-tumors-a-claims-database-analysis
#19
Al B Benson, Michael S Broder, Beilei Cai, Eunice Chang, Maureen P Neary, Elya Papoyan
AIM: To describe real-world treatment patterns of gastrointestinal neuroendocrine tumors (GI NET). METHODS: In this retrospective cohort study, we used 2009-2014 data from 2 United States commercial claims databases to examine newly pharmacologically treated patients using tabular and graphical techniques. Treatments included somatostatin analogues (SSA), cytotoxic chemotherapy (CC), targeted therapy (TT), interferon (IF) and combinations. We identified patients at least 18 years of age, with ≥ 1 inpatient or ≥ 2 outpatient claims for GI NET who initiated pharmacologic treatment from 7/1/09-6/30/14...
September 7, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28947880/current-treatment-options-for-gastroenteropancreatic-neuroendocrine-tumors-with-a-focus-on-the-role-of-lanreotide
#20
REVIEW
Beata Kos-Kudła, Jarosław Ćwikła, Marek Ruchała, Alicja Hubalewska-Dydejczyk, Barbara Jarzab, Jolanta Krajewska, Grzegorz Kamiński
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a large and very diverse group of neoplasms. Clinical presentation of NETs depends on the site of the primary tumor and whether the tumor is functioning (i.e., secreting peptides or neuroamines that produce symptoms). The diagnosis of GEP-NET is further complicated by symptomatic differences that occur depending on the type of secreted peptide or neuroamine. Due to their heterogeneity and unique characteristics, early diagnosis of GEP-NETs is difficult, which increases the likelihood of metastatic disease and reduces the scope of therapeutic possibilities...
2017: Contemporary Oncology Współczesna Onkologia
keyword
keyword
81166
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"